Emerging treatments for the primary headache disorders

Nathaniel M. Schuster, Sarah E. Vollbracht, Alan M. Rapoport

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.

Original languageEnglish (US)
Pages (from-to)109-113
Number of pages5
JournalNeurological Sciences
Volume36
DOIs
StatePublished - May 30 2015

Fingerprint

Primary Headache Disorders
Cluster Headache
Migraine Disorders
Monoclonal Antibodies
Calcitonin Gene-Related Peptide Receptors
Dihydroergotamine
Tryptamines
Vagus Nerve Stimulation
Transcutaneous Electric Nerve Stimulation
Trigeminal Nerve
Transcranial Magnetic Stimulation
Calcitonin Gene-Related Peptide
Brain Diseases
Neuroglia
Ganglia
Therapeutics
Randomized Controlled Trials
Safety
Equipment and Supplies

Keywords

  • Calcitonin gene-related peptide
  • Cluster headache
  • Headache treatment
  • Migraine
  • Neuromodulation

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Emerging treatments for the primary headache disorders. / Schuster, Nathaniel M.; Vollbracht, Sarah E.; Rapoport, Alan M.

In: Neurological Sciences, Vol. 36, 30.05.2015, p. 109-113.

Research output: Contribution to journalArticle

Schuster, Nathaniel M. ; Vollbracht, Sarah E. ; Rapoport, Alan M. / Emerging treatments for the primary headache disorders. In: Neurological Sciences. 2015 ; Vol. 36. pp. 109-113.
@article{64882f8f19f84a589e5d0da64ca7853a,
title = "Emerging treatments for the primary headache disorders",
abstract = "Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.",
keywords = "Calcitonin gene-related peptide, Cluster headache, Headache treatment, Migraine, Neuromodulation",
author = "Schuster, {Nathaniel M.} and Vollbracht, {Sarah E.} and Rapoport, {Alan M.}",
year = "2015",
month = "5",
day = "30",
doi = "10.1007/s10072-015-2133-1",
language = "English (US)",
volume = "36",
pages = "109--113",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Emerging treatments for the primary headache disorders

AU - Schuster, Nathaniel M.

AU - Vollbracht, Sarah E.

AU - Rapoport, Alan M.

PY - 2015/5/30

Y1 - 2015/5/30

N2 - Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.

AB - Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.

KW - Calcitonin gene-related peptide

KW - Cluster headache

KW - Headache treatment

KW - Migraine

KW - Neuromodulation

UR - http://www.scopus.com/inward/record.url?scp=84931266246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931266246&partnerID=8YFLogxK

U2 - 10.1007/s10072-015-2133-1

DO - 10.1007/s10072-015-2133-1

M3 - Article

VL - 36

SP - 109

EP - 113

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -